Caribou Biosciences

Caribou Biosciences
Name	Caribou Biosciences, Inc.
Foundation	0 2011
Founders	Rachel Haurwitz, Jennifer Doudna, Martin Jínek, James Berger
Location	Berkeley, California, United States
Industry	Biotechnology
Products	CRISPR-based therapeutics
Key people	Rachel Haurwitz (CEO & President), Steven Kanner (CSO), Jason O'Byrne (CFO)
Website	https://www.cariboubio.com/

Caribou Biosciences is a clinical-stage biotechnology company pioneering the development of CRISPR-based genome editing technologies for therapeutic applications. Founded by pioneers in the CRISPR field, the company leverages its proprietary chRDNA platform to create advanced cell therapies, with a primary focus on oncology. Headquartered in Berkeley, California, Caribou aims to develop transformative treatments for patients with serious diseases like cancer and autoimmune disorders.

History and founding

Caribou Biosciences was founded in 2011 by Rachel Haurwitz, Jennifer Doudna, Martin Jínek, and James Berger, stemming from foundational CRISPR research conducted at the University of California, Berkeley. The company's inception was closely tied to the groundbreaking discovery of the CRISPR-Cas9 system, for which Jennifer Doudna and Emmanuelle Charpentier were later awarded the Nobel Prize in Chemistry. Early support came from leading venture capital firms, including Fidelity Management and Research Company and PFM Health Sciences. The company established its research operations in Berkeley, California, positioning itself within the vibrant San Francisco Bay Area biotech hub. A significant corporate milestone was its initial public offering on the NASDAQ under the ticker symbol "CRBU" in July 2021.

Technology and CRISPR platform

The core of Caribou's innovation is its proprietary chRDNA (CRISPR hybrid RNA-DNA) platform, which is designed to improve the specificity and efficacy of genome editing. This technology represents an advancement over first-generation CRISPR-Cas9 systems, utilizing engineered guide RNA structures to enhance target recognition and reduce off-target effects. The platform is versatile, enabling various editing strategies including gene knockout, gene insertion, and multiplexed editing. Caribou's suite of tools also includes next-generation CRISPR-Cas enzymes, such as Cas12a and Cas14, which offer distinct advantages for different therapeutic applications. This technological foundation supports the development of sophisticated allogeneic cell therapies intended for broad patient access.

Product pipeline and clinical programs

Caribou's clinical pipeline is centered on CB-010, a leading allogeneic anti-CD19 CAR-T cell therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphoma. This program is notable for being the first allogeneic CAR-T therapy in clinical trials to incorporate a PD-1 knockout, designed to enhance antitumor activity. The company is also advancing CB-011, a therapy targeting B-cell maturation antigen for multiple myeloma, and CB-012, a CAR-T candidate for acute myeloid leukemia. Preclinical programs extend beyond oncology into autoimmune diseases, exploring the potential of edited cells to treat conditions like lupus. These investigational therapies are being evaluated in clinical trials conducted at major research centers like the MD Anderson Cancer Center.

Collaborations and partnerships

Caribou has established several strategic alliances to expand the reach of its technology. A major multi-target collaboration with AbbVie focuses on developing in vivo CRISPR-based therapies for autoimmune diseases. The company also entered a partnership with Lonza Group for the clinical manufacturing of its allogeneic cell therapy candidates. Earlier research collaborations included work with Biogen on neurology targets and with Genus plc on agricultural applications for livestock. These partnerships provide non-dilutive funding, access to complementary expertise in drug development and commercialization, and validate the potential of the chRDNA platform across diverse fields.

Leadership and key personnel

The company is led by co-founder Rachel Haurwitz, who serves as President and Chief Executive Officer, having guided Caribou from its academic origins. The scientific direction is overseen by Chief Scientific Officer Steven Kanner, formerly of Fate Therapeutics. Financial operations are managed by Chief Financial Officer Jason O'Byrne, who previously held roles at Kite Pharma. The board of directors includes notable figures from the biotech investment community, such as Robert Nelsen of ARCH Venture Partners. This leadership team combines deep expertise in CRISPR biology, immunology, oncology, and corporate strategy to advance the company's mission.

Financials and corporate milestones

Caribou transitioned to a publicly traded company following its IPO on the NASDAQ in 2021, raising significant capital to fund its clinical programs. The company's financial strategy involves utilizing proceeds from its offering, alongside payments from partnerships with firms like AbbVie, to advance its research and development activities. Key corporate milestones include the initiation of the Phase 1 clinical trial for CB-010, the designation of CB-010 as an Orphan Drug by the U.S. Food and Drug Administration, and the expansion of its research facilities in Berkeley, California. Ongoing financial resources are directed toward progressing clinical trials, scaling manufacturing capabilities, and exploring new therapeutic applications for its genome editing platform.

Category:Biotechnology companies of the United States Category:Companies based in Berkeley, California Category:CRISPR Category:Companies listed on NASDAQ